Cannabidiol Elevates mTOR Inhibitor Levels In Tuberous Sclerosis Complex Patients

The mTOR inhibitors everolimus and sirolimus have activity against multiple manifestations of tuberous sclerosis complex (TSC) and are approved to treat astrocytomas, angiomyolipomas, lymphangioleiomyomatosis, and epilepsy. Cannabidiol is a novel anticonvulsant medication. There is a lack of information regarding drug-drug interactions between mTOR inhibitors and cannabidiol in clinical practice.

Source: Pediatric Neurology - December 6, 2019 Category: Neurology Authors: Daniel Ebrahimi-Fakhari, Karen D. Agricola, Cynthia Tudor, Darcy Krueger, David Neal Franz Tags: Short Communication Source Type: research